RARE (23) NBTX (49) GPCR (27) URGN (24) ⌘ Pro Terminal →

Phibro Animal Health Corporation (Class A) (PAHC) — RQD Stock Rating Cockpit

$38.88 +0.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $38.81

Phibro Animal Health Corporation (Class A) (PAHC) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.58B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PAHC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Phibro Animal Health Corporation (Class A) (NASDAQ: PAHC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $38.88 (+0.05% 1D, market cap $1.58B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, PAHC ranks #198 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PAHC compare to RARE and NBTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PAHC carries a Roarable D+ (56/100 RQD), trailing P/E of 32.7x, gross margin of 30.9%, and ROIC of 9.9%. By comparison, RARE (Ultragenyx Pharmaceutical Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $1.59B) and NBTX (Nanobiotix S.A.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.59B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while PAHC leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PAHC?

▼

Per PAHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001069899), Phibro Animal Health Corporation (Class A) generated $1.30B in revenue (+27.4% YoY), $48.3M in net income, and $80.1M in free cash flow against $1.41B in total assets and $603.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $38.81 (-0.18%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 6.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PAHC)Realized 20D OHLCV Swing Band: ±7.1%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY PAHC SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)

Altman Z-Score 2.87 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+14/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-1.80% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)

Macro rate sensitivity & RSI-14 (56.9) create a -13 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$36.81+5.4% Next Q

Q2 (-2Q)

Grade C-$38.80-1.1% Next Q

Q3 (-1Q)

Grade C-$38.38+1.3% Next Q

Current

Grade D+$38.88-0.4% Hist 90D α

Trajectory: D (48) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PAHC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, PAHC faces multiple-compression risk if 32.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 28.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($37.12) or 200D SMA ($41.25) invalidates the momentum regime and cuts Target Base ($38.53) toward Bear Floor ($30.05).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PAHC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PAHC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

56.930 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.87>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE33% OF RANGE

L: $28$38.88H: $60

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (31% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PAHC

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

9.9% ROIC with 30.9% gross margin and 5.08% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 2.87 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

23/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like PAHC

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PAHC)

✓Walkthrough of PAHC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PAHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.90%⚡ TESTING RESISTANCE

2026-11-03O $38.86H $38.88L $38.86C $38.88VOL 182.8K

RES: $40.92SUP: $34.17SMA50: $37.12SMA200: $41.25

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PAHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PAHC Butterfly Map → + Track PAHC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PAHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PAHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PAHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAHC)

Health Care Rank #198 of 1016 ⚔️ RARE vs PAHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PAHC vs. RARE, NBTX, GPCR, URGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Phibro Animal Health Corporation (Class A) (PAHC) ranks #198 by composite RQD confidence (56/100, grade D+) and #295 by equity capitalization ($1.58B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while PAHC leads on capital efficiency and profitability with 9.9% ROIC and 30.9% gross margin. PAHC currently leads its immediate peer cohort in composite quantitative strength at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PAHC ACTIVE Phibro Animal Health Corporation (Class A)	D+	56/100	32.7x	30.9%	9.9%	+0.05%	$1.58B	Benchmark Subject
RARE Ultragenyx Pharmaceutical Inc.	E	23/100	—	—	-35.0%	-4.05%	$1.59B	/rare-vs-pahc →
NBTX Nanobiotix S.A.	D	49/100	—	—	—	-7.19%	$1.59B	/nbtx-vs-pahc →
GPCR Structure Therapeutics Inc.	E	27/100	—	—	-19.5%	-0.32%	$1.56B	/gpcr-vs-pahc →
URGN UroGen Pharma Ltd.	E	24/100	—	88.7%	-35.0%	-2.27%	$1.60B	/urgn-vs-pahc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001069899

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Phibro Animal Health Corporation (Class A) (PAHC) reported GAAP revenue of $1.30B (+27.4% vs. FY2024 revenue of $1.02B , and +32.6% cumulative change since FY2023) , GAAP net income of $48.3M, operating cash flow of $80.1M, and free cash flow of $80.1M (-8.5% YoY). On the balance sheet, PAHC closed FY2025 with $1.41B in total assets against $603.6M in total debt (Altman Z-Score: 2.87, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$1.30B	$48.3M	$80.1M	$80.1M	$1.41B	$603.6M
FY2024 (FY)	2024-06-30	$1.02B	$2.4M	$87.6M	$87.6M	$1.29B	$622.9M
FY2023 (FY)	2023-06-30	$977.9M	$32.6M	$13.3M	$13.3M	—	—

3. PAHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PAHC compare to RARE and NBTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PAHC?

Where is PAHC trading relative to its 50-day, 200-day, and 52-week technical levels?

PAHC last traded at $38.88 (+0.05% on volume of 182,794 shares), positioning the stock +4.74% above its 50-day simple moving average ($37.12) and -5.75% below its 200-day simple moving average ($41.25). Across its 52-week range of $28.25 to $60.08, PAHC sits at the 33.4% percentile with a 14-day RSI of 56.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.1% ($36.12 to $41.64).

PAHC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PAHC stock right now?

Phibro Animal Health Corporation (Class A) (PAHC) currently earns a Roarable Rating of D+ (Sell — SELL) with 56/100 RQD Confidence. Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.

What is PAHC's 12-month price target and RQD AI Jury consensus?

PAHC's 12-month base price target is $38.53 (range $30.05 to $63.08), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PAHC RQD Cockpit PAHC 12M Forecast PAHC Earnings & Move PAHC Dividends & DRIP PAHC Insiders & 13F PAHC Whale Options PAHC Profit Sankey PAHC News & Why

ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PAHC — Phibro Animal Health Corporation (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:28:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PAHC scores 56 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental cash engine: 12 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 9.9% and an FCF yield of 5.08%. Returns on capital are positive but not strong, and the cash yield is moderate relative to the price.
Whale 13F flow: 9 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, indicating limited smart-money support in the source data.
Insider conviction: 14 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the strongest pillar but still below the midpoint.
Macro regime fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector sensitivity assessment. This is the weakest pillar, suggesting the stock's risk profile is not favorably positioned for the current regime.
Forensic balance sheet: 14 / 20. Per the Roarable RQD rating, the Altman Z-Score is 2.87, the Piotroski F-Score is 8/9, and Debt/Equity is 1.82. Balance-sheet quality is a relative strength, but leverage is elevated.

For a prospective investor, the composite reading points to a stock where the fundamental and forensic profile is mixed, the ownership and macro signals are weak, and the valuation carries a premium on earnings. Upside drivers would need to come from margin expansion or sustained cash generation; the valuation tradeoff is that forward P/E of 27.5 and EV/EBITDA of 19.2 already price in meaningful improvement. The rating's "Trim" verdict signals that the source data does not support adding exposure on current evidence.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
38.86	$1.58B	32.7	27.5	19.2	1.19	1.23%	1.0	$28.25 - $60.08	9.9%

Business

Phibro Animal Health Corporation (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company operates with a market capitalization of $1.6B. Per the SEC financials, reported FY 2025 revenue was $1296.2M. Specific product lines, customer segments, and monetization model are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1296.2M	$110.5M	$48.3M	N/A	$80.1M	$55.5M	$603.6M
FY 2024	$1017.7M	$53.3M	$2.4M	N/A	$87.6M	$67.1M	$622.9M
FY 2023	$977.9M	$71.8M	$32.6M	N/A	$13.3M	N/A	N/A

Per the market data, gross margin is 30.9%, operating margin 8.5%, and net margin 3.7%, with ROIC of 9.9%. Per the RQD rating, the Altman Z-Score is 2.87 and the Piotroski F-Score is 8/9, both supportive of financial health. Debt/Equity of 1.82 per the RQD rating indicates meaningful leverage; reported debt was $603.6M in FY 2025 against cash of $55.5M.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference PAHC, all flagged YELLOW with a MARKET WIRE impact label. Headlines reference market action and institutional positioning (Yahoo Finance, TradingView, Simply Wall St), a stock forecast and analyst predictions article, and a webcast and conference call announcement for first-quarter results. No specific operational event, earnings figure, or deal is stated in the headline or summary text. Per the Butterfly Supply-Chain Graph, no proprietary signals are present. The first-quarter results webcast is a scheduled catalyst to monitor; its content is not available in source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are not available in source data. The sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is the only contextual anchor provided. Second-order bottlenecks cannot be identified from the supplied material.

Open Questions

What are the specific drivers of the FY 2025 revenue increase and the swing in net income from $2.4M to $48.3M, and are they recurring?
What is the reported EPS for each period, given that the source lists EPS as N/A for all reported years?
What is the FY 2023 cash and debt position, and how has leverage trended across the three periods?
What were the outcomes and guidance from the upcoming or recent first-quarter results webcast?
Which institutional holders and insiders have transacted in PAHC, and in what direction?

PAHC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Phibro Animal Health Corporation (Class A) (PAHC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PAHC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 18h ago

What Is Drawing Attention To Phibro Animal Health (PAHC) Today?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Phibro Animal Health Corporation Estimates – NASDAQ:PAHC

TradingView report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Phibro Animal Health (NasdaqGM:PAHC) Stock Forecast & Analyst Predictions

Simply Wall St report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

TradingView report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

PAHC vs. HAE: Which Stock Is the Better Value Option?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

PAHC or SYK: Which Is the Better Value Stock Right Now?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PAHC Bull vs. Bear Conversation Board — What's Your Call at $38.88?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PAHC 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $41.97 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PAHC (D+ • RQD 56/100) a Buy at $38.86?

Welcome to the PAHC (Phibro Animal Health Corporation (Class A)) Roar Pit. Current RQD Composite is 56/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.7x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $30.70 (-21.0%)

Spot @ $38.86

Pump the brakes on PAHC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PAHC, but look at what you are paying: 32.7x trailing P/E with 30.9% gross margins. Unless Phibro Animal Health Corporation (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $46.24 (+19.0%)

Spot @ $38.86

PAHC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PAHC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $38.86 (52-wk range $28.25 - $60.08), any beat on forward guidance forces shorts and underweight funds to chase.